Neuland Laboratories Limited Share Price NSE India S.E.

Equities

NEULANDLAB

INE794A01010

Pharmaceuticals

Market Closed - NSE India S.E. 12:43:48 26/04/2024 BST 5-day change 1st Jan Change
6,973 INR -1.67% Intraday chart for Neuland Laboratories Limited -5.36% +31.79%

Financials

Sales 2024 * 15.83B 190M 15.19B Sales 2025 * 16.39B 197M 15.73B Capitalization 89.6B 1.07B 86.03B
Net income 2024 * 3.11B 37.28M 2.98B Net income 2025 * 3.19B 38.24M 3.06B EV / Sales 2024 * 5.52 x
Net cash position 2024 * 2.32B 27.89M 2.23B Net cash position 2025 * 4.33B 51.94M 4.16B EV / Sales 2025 * 5.2 x
P/E ratio 2024 *
29 x
P/E ratio 2025 *
28.3 x
Employees 1,554
Yield 2024 *
0.17%
Yield 2025 *
0.14%
Free-Float 63.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.67%
1 week-5.36%
Current month+10.30%
1 month+9.65%
3 months+14.40%
6 months+83.82%
Current year+31.79%
More quotes
1 week
6 818.45
Extreme 6818.45
7 721.90
1 month
5 989.95
Extreme 5989.95
7 790.00
Current year
5 021.10
Extreme 5021.1
7 790.00
1 year
2 009.05
Extreme 2009.05
7 790.00
3 years
967.00
Extreme 967
7 790.00
5 years
245.75
Extreme 245.75
7 790.00
10 years
245.75
Extreme 245.75
7 790.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 31/12/01
Director of Finance/CFO - 22/11/22
Chief Tech/Sci/R&D Officer - 11-21
Members of the board TitleAgeSince
Director/Board Member 78 30/10/22
Director/Board Member 80 11/02/19
Director/Board Member 60 26/06/23
More insiders
Date Price Change Volume
26/04/24 6,973 -1.67% 30,728
25/04/24 7,092 -1.77% 22,889
24/04/24 7,220 -4.20% 33,521
23/04/24 7,537 -1.20% 15,116
22/04/24 7,628 +3.52% 29,991

Delayed Quote NSE India S.E., April 26, 2024 at 12:43 pm

More quotes
Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The Company provide solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6,984 INR
Average target price
8,300 INR
Spread / Average Target
+18.85%
Consensus

Quarterly revenue - Rate of surprise